GSK plc revealed on Wednesday that its turnover reached £7.38 billion in the fourth quarter of fiscal 2022, while full-year sales jumped 19% to reach £29.32 billion.
The results showed the yearly adjusted operating profit rose 26% to £8.15 billion, marking another leap of 21% in the fourth quarter to take the total to £1.59 billion. Further, adjusted earnings per share amounted to 25.8 pence for the fourth quarter, and on a yearly basis it rose 27% to 139.7 pence.
"2022 was a landmark year for GSK delivering the step change in performance we committed to, driven by strong growth in specialty medicines and vaccines," CEO Emma Walmsley commented and further adding, "this momentum, together with further targeted business development, means GSK will also be in a strong position to deliver growth from 2026 onwards."
The 2023 full-year guidance expects turnover to increase between 6% to 8%. GSK's shares were up 0.40% in the premarket trading.
